Par Drugs And Chemicals Limited
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, m… Read more
Par Drugs And Chemicals Limited (PAR) - Net Assets
Latest net assets as of September 2025: ₹1.06 Billion INR
Based on the latest financial reports, Par Drugs And Chemicals Limited (PAR) has net assets worth ₹1.06 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.28 Billion) and total liabilities (₹210.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.06 Billion |
| % of Total Assets | 83.46% |
| Annual Growth Rate | 21.34% |
| 5-Year Change | 89.55% |
| 10-Year Change | N/A |
| Growth Volatility | 11.23 |
Par Drugs And Chemicals Limited - Net Assets Trend (2016–2025)
This chart illustrates how Par Drugs And Chemicals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Par Drugs And Chemicals Limited (2016–2025)
The table below shows the annual net assets of Par Drugs And Chemicals Limited from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹989.75 Million | +15.58% |
| 2024-03-31 | ₹856.32 Million | +20.21% |
| 2023-03-31 | ₹712.38 Million | +18.97% |
| 2022-03-31 | ₹598.77 Million | +14.68% |
| 2021-03-31 | ₹522.15 Million | +28.56% |
| 2020-03-31 | ₹406.15 Million | +39.49% |
| 2019-03-31 | ₹291.17 Million | +40.67% |
| 2018-03-31 | ₹206.99 Million | +7.79% |
| 2017-03-31 | ₹192.03 Million | +10.65% |
| 2016-03-31 | ₹173.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Par Drugs And Chemicals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 759.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹759.29 Million | 76.72% |
| Common Stock | ₹123.05 Million | 12.43% |
| Other Comprehensive Income | ₹686.00K | 0.07% |
| Other Components | ₹106.73 Million | 10.78% |
| Total Equity | ₹989.75 Million | 100.00% |
Par Drugs And Chemicals Limited Competitors by Market Cap
The table below lists competitors of Par Drugs And Chemicals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CREDICORP
BE:D8V
|
$2.45 Million |
|
Palatin Technologies Inc
NYSE MKT:PTN
|
$2.45 Million |
|
RENAISSANCERE HLDG
BE:RRJ
|
$2.45 Million |
|
UCB - Dusseldorf Stock Exchang
DU:UNC
|
$2.45 Million |
|
Saigon General Service Corp
VN:SVC
|
$2.44 Million |
|
JATCORP LTD.
F:3J2
|
$2.44 Million |
|
TURA GROUP AB
F:8WO
|
$2.44 Million |
|
CARLO GAVAZZI
BE:D9N
|
$2.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Par Drugs And Chemicals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 856,320,000 to 989,749,000, a change of 133,429,000 (15.6%).
- Net income of 133,579,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 350,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹133.58 Million | +13.5% |
| Other Comprehensive Income | ₹-350.00K | -0.04% |
| Other Changes | ₹200.00K | +0.02% |
| Total Change | ₹- | 15.58% |
Book Value vs Market Value Analysis
This analysis compares Par Drugs And Chemicals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.33x to 1.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | ₹14.11 | ₹89.34 | x |
| 2017-03-31 | ₹15.61 | ₹89.34 | x |
| 2018-03-31 | ₹16.82 | ₹89.34 | x |
| 2019-03-31 | ₹23.66 | ₹89.34 | x |
| 2020-03-31 | ₹33.03 | ₹89.34 | x |
| 2021-03-31 | ₹42.49 | ₹89.34 | x |
| 2022-03-31 | ₹48.66 | ₹89.34 | x |
| 2023-03-31 | ₹57.90 | ₹89.34 | x |
| 2024-03-31 | ₹69.59 | ₹89.34 | x |
| 2025-03-31 | ₹80.47 | ₹89.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Par Drugs And Chemicals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.50%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.23%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.21x
- Recent ROE (13.50%) is above the historical average (12.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.43% | 1.27% | 0.57x | 3.34x | ₹-13.14 Million |
| 2017 | 9.62% | 3.96% | 0.83x | 2.92x | ₹-725.30K |
| 2018 | 7.22% | 3.56% | 0.78x | 2.61x | ₹-5.75 Million |
| 2019 | 8.31% | 5.30% | 0.89x | 1.76x | ₹-4.93 Million |
| 2020 | 11.73% | 8.65% | 0.92x | 1.48x | ₹7.04 Million |
| 2021 | 22.24% | 19.39% | 0.78x | 1.46x | ₹63.90 Million |
| 2022 | 15.39% | 12.35% | 0.95x | 1.31x | ₹32.26 Million |
| 2023 | 15.91% | 11.92% | 1.07x | 1.25x | ₹42.10 Million |
| 2024 | 16.93% | 15.16% | 0.94x | 1.19x | ₹59.38 Million |
| 2025 | 13.50% | 13.23% | 0.85x | 1.21x | ₹34.60 Million |
Industry Comparison
This section compares Par Drugs And Chemicals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Par Drugs And Chemicals Limited (PAR) | ₹1.06 Billion | 2.43% | 0.20x | $2.45 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |